Animal models have provided evidence supporting the role of RB1 loss in selectively affecting tumors of neuroendocrine origin, which supported the similarity between LCNECs and SCLC.[70] Recent data has revealed that high levels of mitogen-activated protein kinase (MAPK) activation may prevent ADC from adopting a neuroendocrine identity. Here, RB1 is linked to small cell lung carcinoma.